Vetter Receives “Known Consignor” Approval from Germany's Federal Aviation Office
News Dec 12, 2012
Vetter has announced that it has now been approved as a “Known Consignor” by the German Federal Aviation Office. The agency officially granted the pharmaceutical service provider the certificate of approval following an audit at Vetter´s Holbeinstrasse and Ravensburg Vetter West facilities.
The approval means that customers will continue to have their air cargo products loaded, transported and delivered quickly and safely, saving valuable time and money.
Vetter had already been designated as a “Known Consignor” back in 2006. The goal of the certification is primarily to provide more security for air cargo.
Until recently, logistics companies themselves issued the certificate. New EU regulations concerning the so-called "safe supply chains" require that companies must now have their status audited and approved by the Federal Aviation Office.
The criteria for certification are extensive and include elaborating a safety concept, training personnel, and the assurance that the shipping of freight is performed in a way that cannot be tampered with.
Any attempt to open the shipment would be immediately evident. The Federal Aviation Office grants the certificate for five years and carries out unannounced controls on a regular basis.
"Our approval as a "Known Consignor" allows our customers fast and smooth loading of air freight packages at the airport, including a high level of security,” said managing director Thomas Otto.
Otto continued, “Once time-consuming x-rays and searches are no longer necessary, saving invaluable effort and cost. For Vetter, the status of ”Known Consignor” is further proof of the high product quality that we offer our customers.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE